Literature DB >> 21073863

Inhibition of neurotrophin receptor p75 intramembran proteolysis by gamma-secretase inhibitor reduces medulloblastoma spinal metastasis.

Xiaoji Wang1, Min Cui, Lei Wang, XueHong Chen, Pan Xin.   

Abstract

Medulloblastoma (MB) is the most devastating and common pediatric brain tumor. Tumor cells invading into surrounding tissue and disseminating through cerebrospinal fluid make treatment extremely difficult. Identifying the mechanisms of MB cells is therefore imperative for the development of novel treatments. A research group demonstrated recently that the multifunctional signaling protein neurotrophin receptor p75(NTR) is a central regulator for glioma invasion. γ-secretase mediated processing of the p75(NTR) is a major contributor to the highly invasive nature of malignant gliomas. In this study we examine the p75(NTR) expression and processing in medulloblastoma cells. Results show that p75(NTR) is a critical regulator of medulloblastoma spinal metastasis. γ-secretase inhibitor, which blocks p75(NTR) proteolytic processing, significantly abrogates p75(NTR) induced medulloblastoma migration and invasion in vitro and in vivo. This data suggests that p75(NTR) is also an important therapeutic target for MB. γ-secretase inhibitor may be a potentially effective clinical application for the treatment of medulloblastoma spinal metastasis.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21073863     DOI: 10.1016/j.bbrc.2010.11.012

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Receptor tyrosine kinases in the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-10-01       Impact factor: 10.005

Review 2.  The Unwanted Cell Migration in the Brain: Glioma Metastasis.

Authors:  Xue Tao Qi; Jiang Shan Zhan; Li Ming Xiao; Lina Li; Han Xiao Xu; Zi Bing Fu; Yan Hao Zhang; Jing Zhang; Xi Hua Jia; Guo Ge; Rui Chao Chai; Kai Gao; Albert Cheung Hoi Yu
Journal:  Neurochem Res       Date:  2017-05-06       Impact factor: 3.996

3.  Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes.

Authors:  Ludivine Coudière Morrison; Robyn McClelland; Christopher Aiken; Melissa Bridges; Lisa Liang; Xin Wang; Domenico Di Curzio; Marc R Del Bigio; Michael D Taylor; Tamra E Werbowetski-Ogilvie
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

4.  p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.

Authors:  Iram Ahmad; Wei Ying Yue; Augusta Fernando; J Jason Clark; Erika A Woodson; Marlan R Hansen
Journal:  Glia       Date:  2014-06-26       Impact factor: 7.452

Review 5.  The rationale for targeted therapies in medulloblastoma.

Authors:  Tobey J MacDonald; Dolly Aguilera; Robert C Castellino
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

6.  Sensitivity of edge detection methods for quantifying cell migration assays.

Authors:  Katrina K Treloar; Matthew J Simpson
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

7.  γ-secretase inhibitors, DAPT and RO4929097, promote the migration of Human Glioma Cells via Smad5-downregulated E-cadherin Expression.

Authors:  Shun-Fu Chang; Wei-Hsun Yang; Chun-Yu Cheng; Sheng-Jie Luo; Ting-Chung Wang
Journal:  Int J Med Sci       Date:  2021-04-26       Impact factor: 3.738

8.  Development of functionalized multi-walled carbon-nanotube-based alginate hydrogels for enabling biomimetic technologies.

Authors:  Binata Joddar; Eduardo Garcia; Atzimba Casas; Calvin M Stewart
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379

9.  Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes.

Authors:  Lisa Liang; Christopher Aiken; Robyn McClelland; Ludivine Coudière Morrison; Nazanin Tatari; Marc Remke; Vijay Ramaswamy; Magimairajan Issaivanan; Timothy Ryken; Marc R Del Bigio; Michael D Taylor; Tamra E Werbowetski-Ogilvie
Journal:  Oncotarget       Date:  2015-11-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.